What to Expect When Walgreens Reports Thursday

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
What to Expect When Walgreens Reports Thursday

© Anthony92931 / Wikimedia Commons

Walgreens Boots Alliance Inc. (NASDAQ: WBA) is scheduled to release its fiscal first-quarter financial results before the markets open on Thursday. The consensus estimates are calling for $1.44 in earnings per share (EPS) and $33.75 billion in revenue. In the same period of last year, the specialty retailer said it had $1.28 in EPS and $30.74 billion in revenue.

In its most recent quarter, the company’s U.S. retail pharmacy division posted an increase of 14.4% year over year. Total same-store sales rose 0.3% in the quarter. Pharmacy sales accounted for nearly three-quarters (73.6%) of the division’s revenue, up 16.7% year over year. The increase was attributed to higher volume resulting from the acquisition of 1,932 Rite Aid stores that was completed earlier this year. Same-store pharmacy sales rose 1.3%, reflecting the higher volume.

At the same time, quarterly U.S. non-pharmacy retail sales dropped by 1.9% year over year, even though total sales were 8.3% higher due to the Rite Aid acquisition. Walgreens noted declines in sales of consumables, general merchandise and personal care products, partially offset by growth in health and wellness and beauty products.

Also, sales in the company’s international retail pharmacy business dropped 1.9% year over year in the fourth quarter and were down 2.7% on a constant currency basis. Same-store pharmacy sales were down 3.4% and retail sales were down 0.9% due to a drop in Boots UK beauty products sales.

[nativounit]

Walgreens has outperformed the broad markets, with its stock up about 5% in the past 52 weeks. In the past six months, the stock is up closer to 17%.

A few analysts weighed in on Walgreens ahead of the report:

  • Goldman Sachs has a Sell rating.
  • Morgan Stanley has an Equal Weight rating and a $77 price target.
  • Pivotal Research has a Hold rating with a $72 price target.
  • Barclays has an Equal Weight rating and an $80 price target.
  • Robert Bard has a Neutral rating with a $71 price target.
  • Citigroup has a Neutral rating with a $76 price target.
  • SunTrust Banks has Hold rating with a $75 price target.
  • Loop Capital has a Buy rating with an $82 price target.

Shares of Walgreens were last seen trading at $75.81, in a 52-week range of $59.07 to $86.31. The consensus analyst price target is $78.59.

[recirclink id=513404]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618